Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025
Seer (Nasdaq: SEER) announced new data to be presented at the Human Proteome Organization (HUPO) World Congress 2025 on Nov 10–12, 2025. More than a dozen scientific presentations—including two invited talks in Seer’s breakfast symposium on Nov 10, 2025—showcase the Proteograph® platform applied across cardiovascular, oncology, and aging biology.
Highlights include deep plasma and tissue proteomics identifying candidate biomarkers for right ventricular failure, aging-related mediators from mouse serum, and multi-cancer and extracellular vesicle proteome studies, underscoring scalability and translational potential for population-scale research.
Seer (Nasdaq: SEER) ha annunciato nuovi dati da presentare al World Congress HUPO 2025 dell'Human Proteome Organization dal 10 al 12 novembre 2025. Più di una dozzina di presentazioni scientifiche—including due interventi invitati nel breakfast symposium di Seer il 10 novembre 2025—mostrano la piattaforma Proteograph® applicata in ambito cardiovascolare, oncologico e di biologia dell'invecchiamento.
Evidenze principali includono proteomica profonda del plasma e dei tessuti che identificano potenziali biomarcatori per l'insufficienza del ventricolo destro, mediatori legati all'invecchiamento dal siero di topo, e studi sul proteoma di molteplici tipi di cancro e sulle vescicole extracellulari, sottolineando scalabilità e potenziale di traduzione per la ricerca su scala di popolazione.
Seer (Nasdaq: SEER) anunció nuevos datos que se presentarán en el World Congress HUPO 2025, de la Organización de Proteómica Humana, del 10 al 12 de noviembre de 2025. Más de una docena de presentaciones científicas—including dos charlas invitadas en el breakfast symposium de Seer el 10 de noviembre de 2025—muestran la plataforma Proteograph® aplicada en cardiovascular, oncología y biología del envejecimiento.
Entre los aspectos destacados se encuentran la proteómica profunda del plasma y de tejidos que identifica biomarcadores candidatos para la insuficiencia del ventrículo derecho, mediadores relacionados con el envejecimiento en suero de ratón y estudios sobre el proteoma de múltiples tipos de cáncer y vesículas extracelulares, subrayando la escalabilidad y el potencial de traducción para la investigación a escala poblacional.
Seer (나스닥: SEER)는 Human Proteome Organization HUPO World Congress 2025에서 2025년 11월 10일~12일에 발표될 새로운 데이터를 발표했습니다. Seer의 브레이크퍼스트 심포지엄에서 2025년 11월 10일에 초청 강연 2회를 포함한 11편이 넘는 과학 발표가 Proteograph® 플랫폼이 심혈관계, 종양학 및 노화 생물학 전반에 적용되는 것을 보여줍니다.
주요 내용으로는 혈장 및 조직의 심층 프로테오믹스가 우심실 부전의 후보 바이오마커를 식별하고, 생쥐 혈청에서 노화 관련 매개체가 발견되며, 다발성 암 및 세포외 소포체 프로테옴 연구가 포함되어 확장성과 인구 규모 연구에 대한 번역 가능성을 강조합니다.
Seer (Nasdaq: SEER) a annoncé de nouvelles données qui seront présentées au World Congress HUPO 2025 de l'Human Proteome Organization, du 10 au 12 novembre 2025. Plus d'une douzaine de présentations scientifiques—including deux communications invitées dans le symposium petit-déjeuner de Seer le 10 novembre 2025—montrent la plateforme Proteograph® appliquée dans les domaines cardiovasculaire, oncologie et biologie du vieillissement.
Parmi les temps forts figurent une protéomique profonde du plasma et des tissus identifiant des biomarqueurs candidats pour l'insuffisance ventriculaire droite, des médiateurs liés au vieillissement issus du sérum de souris, et des études sur le proteome de multiples cancers et sur les vésicules extracellulaires, soulignant l'évolutivité et le potentiel translationnel pour la recherche à l'échelle populationnelle.
Seer (Nasdaq: SEER) hat neue Daten angekündigt, die beim HUPO World Congress 2025 der Human Proteome Organization vom 10. bis 12. November 2025 präsentiert werden sollen. Mehr als ein Dutzend wissenschaftliche Vorträge—including zwei eingeladene Vorträge im Seer Frühstückssymposium am 10. November 2025—zeigen die Proteograph®-Plattform in Anwendungen in der Herz-Kreislauf-Morschung, Onkologie und Alterungsbiologie.
Zu den Höhepunkten gehören tiefe Plasma- und Gewebe-Proteomik-Analysen, die potenzielle Biomarker für das Rechtsherzinsversagen identifizieren, altersbedingte Mediatoren aus dem Mausserum, sowie Studien zum Proteom von mehreren Krebsarten und zu extrazellulären Vesikeln, die Skalierbarkeit und translationales Potenzial für bevölkerungsbasierte Forschung unterstreichen.
سيير (نازداك: SEER) أعلنت عن بيانات جديدة ستُعرض في World Congress HUPO لعام 2025 لمنظمة البروتين البشري، من 10 إلى 12 نوفمبر 2025. أكثر من عشرة عروض علمية—بما في ذلك محاضرتان مدعوّتان في جلسة الفطور (Breakfast Symposium) لسيير في 10 نوفمبر 2025—تظهر منصة Proteograph® مطبقة عبر مجالات القلب والأوعية الدموية، الأورام، وبيولوجيا الشيخوخة.
من بين أبرز النقاط البروتيومية العميقة للدم البروتيني والأنسجة التي تحدد احتمالية وجود علامات حيوية للكفاءة البطينية اليمنى، والوسطاء المرتبطين بالشيخوخة من مصل الفئران، ودراسات عن بروتوم عدة أنواع من السرطان وبروتومات الحويصلات خارج الخلوية، مع التأكيد على قابلية التوسع والإمكانات الترجمية للأبحاث على مستوى السكان.
- None.
- None.
Studies spanning cardiovascular, aging, and cancer biology highlight how Seer’s Proteograph® platform is enabling discovery at population scale
REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced new data to be featured at the Human Proteome Organization (HUPO) World Congress 2025, underscoring how deep, scalable proteomics is transforming the study of human disease. Through a combination of Seer-led, collaborative, and independent studies, the company’s Proteograph Product Suite is powering a growing body of research across cardiovascular, oncology, and aging biology. Collectively, these findings demonstrate how Seer’s technology is enabling scientists worldwide to translate complex biological signatures into actionable understanding, bringing proteomics to the forefront of translational and population-scale research.
Seer’s presence at HUPO 2025 represents one of the most comprehensive demonstrations of its technology to date, with more than a dozen scientific presentations, including two invited talks in the company’s breakfast symposium and sixteen posters presented across three days of sessions. Together, these studies highlight the accelerating adoption of Seer’s Proteograph platform and its growing impact across diverse biological and clinical research areas.
“The studies presented at HUPO demonstrate that proteomics has reached a new stage of scalability and relevance,” said Omid Farokhzad, Chair and CEO of Seer. “We are seeing proteomics move from specialized studies to population-scale discovery that bridges molecular insights to real clinical translation. Seer’s Proteograph platform continues to be the catalyst making that possible, empowering researchers to go deeper, broader, and faster than ever before.”
Seer Breakfast Symposium
Proteomic Breakthroughs in Cardiac Dysfunction and Aging-Related Decline
Date: November 10, 2025 | Time: 8:00–9:00 a.m. ET | Location: Room Pier 2+3
Speakers:
Nathan Basisty, PhD, NIH Distinguished Scholar and Investigator, National Institute on Aging
Uros Kuzmanov, PhD, Senior Research Associate, University of Toronto and Ted Rogers Centre for Heart Research
This session will highlight the use of deep plasma and tissue proteomics to illuminate disease mechanisms and reveal clinically relevant biomarkers in cardiovascular and aging biology. Dr. Basisty will share how deep proteomic analysis of mouse serum uncovered paracrine mediators of physical dysfunction caused by senescent cells. Dr. Kuzmanov will present findings from a proteomic study of paired myocardial and serum samples from patients with end-stage heart disease that identified candidate biomarkers of right ventricular failure. Together, these talks showcase the power of Seer’s technology to uncover novel biomarkers, link circulating proteins to disease mechanisms, and accelerate translational insights for cardiovascular failure and aging-related decline.
Scientific Presentations Featuring Seer Technology
Scalable Plasma Proteomics Workflow Reveals Disease Insights Using the Seer Proteograph Workflow and the Thermo Scientific Orbitrap Astral Mass Spectrometer — Presenter: S. Maity | Poster Viewing I | November 10, 1:15–3:15 p.m.
Comprehensive and High-Throughput Plasma Proteome Profiling for Biomarker Discovery Using a Modified Orbitrap Astral Mass Spectrometer — Presenter: S. Samra | Poster Viewing I | November 10, 1:15–3:15 p.m.
Tools to Explore Complex Glycoproteomics Data — Presenter: N. Riley | Poster Viewing I | November 10, 1:15–3:15 p.m.
Deep Proteomic Profiling of Paired Myocardial and Serum Samples Identifies Biomarkers of Right Ventricular Failure in LVAD Patients — Presenter: D. Davoudpour | Poster Viewing II | November 11, 1:15–3:15 p.m.
Plasma Proteome Profiling in Acute Decompensated Heart Failure Reveals Biomarkers Predictive of Readmission Risk — Presenter: M. Di Paola | Poster Viewing II | November 11, 1:15–3:15 p.m.
Expanding the Landscape of Biomarker Discovery in a Multi-Cancer Cohort — Presenter: D. Gutierrez | Poster Viewing II | November 11, 1:15–3:15 p.m.
LC-MS Workflows for Diverse Omics Analysis of Plasma Samples in a Mini Cancer Cohort Using the Orbitrap Astral Mass Spectrometer — Presenter: S. Peterman | Poster Viewing II | November 11, 1:15–3:15 p.m.
Alternative Protein Isoform Biomarkers Predicting Differential Survival in Idiopathic Pulmonary Fibrosis — Presenter: J. Korchak | Poster Viewing II | November 11, 1:15–3:15 p.m.
Ultra-Deep and Reproducible Proteomic Profiling of Extracellular Vesicles with the Proteograph® Platform: Uncovering the Hidden Landscape of EV Biology — Presenter: A. Gajadhar | Poster Viewing II | November 11, 1:15–3:15 p.m.
A Fast, Sensitive and Accurate Search Engine for Quantitative DIA Proteomics — Presenter: L. Cantrell | Poster Viewing II | November 11, 1:15–3:15 p.m.
Systematic Evaluation of Enrichment and Analytical Methods for CSF Proteomics — Presenter: A. Aastha | Poster Viewing III | November 12, 1:15–3:15 p.m.
Comparative Analysis of Enrichment Workflows for Optimized Profiling of EVs in Plasma — Presenter: M. Bok | Poster Viewing III | November 12, 1:15–3:15 p.m.
An Update on the Fundamental Biological Determinants of the Plasma Proteome Using Proteograph Assay and Murine Models — Presenter: M. Chang | Poster Viewing III | November 12, 1:15–3:15 p.m.
Investigating the Role of NETosis in the Migration and Invasion of Bladder Cancer Cells — Presenter: E. Bang | Poster Viewing III | November 12, 1:15–3:15 p.m.
Deep Plasma Proteomics Using Bead-Based Approaches in Combination with LC-MS/MS Analysis: How Is the Next Generation of Technologies Performing — Presenter: C. Kluger | Poster Viewing III | November 12, 1:15–3:15 p.m.
Characterization of the Mechanism of Resistance to EZT Treatment in Prostate Cancer Using Secretome Analysis — Presenter: M. Kim | Poster Viewing III | November 12, 1:15–3:15 p.m.
For more information, please visit booth #801 or contact us at pr@seer.bio.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
FAQ
When will Seer present at HUPO 2025 and what sessions involve SEER?
What topics will Seer (SEER) cover at HUPO 2025?
Which Seer (SEER) session discusses biomarkers for right ventricular failure?
How is Seer positioning the Proteograph platform at HUPO 2025?
Where can investors or attendees find Seer at HUPO 2025?
Will Seer present invited talks at HUPO 2025 and who are the speakers?
